Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Evaluate's commercial intelligence on the pharmaceutical, biotechnology, and medical device industries is consistently referenced by leading business and industry publications such as the Financial Times, Wall Street Journal, and Nature.
Download our latest Media Kit for a forward-looking view of top companies, products, and more to support your editorial content.
Vantage releases its half-year analysis of sector performance: Pharma, Biotech and Medtech Half-Year Review 2018
Eleventh annual EvaluatePharma World Preview 2018, Outlook to 2024 report launches at BIO 2018.
Annual “EvaluatePharma Orphan Drug 2018 Report” sees Orphan drugs capture a fifth of worldwide prescription sales by 2024 as sales grow to $262bn.
The Massachusetts Biotechnology Council (MassBio) released its 2018 Industry Snapshot report, in partnership with EvaluatePharma, which shows Massachusetts biotechs…
Money flooded into initial public offerings (IPOs) and venture financing for young biotech companies in the first half of 2018, according to a report by Vantage, the…
GlaxoSmithKline is already working hard to convince the HIV world that its once-daily, two-pill regimen is as good as established triplet or quad treatments at keeping…